에서 실시간으로 운영 중이에요! 자세히 알아보기

SHLT

SHL Telemedicine Ltd American Depositary Shares

SHLT

시가총액 US$3360만

상장 폐지됨

SHLT은(는) 2025년 4월 2일에 상장 폐지됐어요.

순위로 돌아가기

소개: SHL Telemedicine Ltd develops and markets personal telemedicine solutions. It consists of the transmission of medical data by an individual, from a remote location to a medical call center through telecommunication networks. The company offers solutions to subscribing patients, health insurance companies, hospitals, clinics, and physicians. It provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments Israel, Europe, and the rest of the world, out of which majority revenue comes from Israel.

직원 수: 583

건강관리 의료 시설

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced cardiovascular diagnostics to patients' homes and underserved communities i.

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level managem.

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it is in discussions with Discount Capital Ltd. the investment arm of Israel Discount Bank, regarding a possible investment relating to SHL's Israeli activity. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to.

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home Biomarker blood tests. This diagnostic tool is designed to rapidly identify cardiac markers for detection of a heart attack, transforming emergency cardiac care with sp.

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

TEL AVIV, Israel & ZURICH, & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it's SmartHeart® membership program in the US. This announcement comes after the highly successful soft launch that was announced in November 2023, which exceeded the company's expectations, demonstrating substantial demand and.

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation. In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL's Israel operatio.

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care

TEL AVIV & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL's SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) pa.

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care

SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company's SmartHeart®, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, “i.

SHL Telemedicine's SmartHeart® Technology Triumphs in US Army Project Convergence – Capstone 4 Experiment

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN; NASDAQ: SHLT) ("SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET. The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO,.

SHL Telemedicine: Invitation to Conference Call Presenting Annual Results 2023

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)---- $SHLT--SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target. This price target represents a significant premium over the company's current share price, highlighting the firm's confidence in S.

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.